Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2015, Article ID 632902, 9 pages
http://dx.doi.org/10.1155/2015/632902
Review Article

Cell Adhesion and Long-Term Survival of Transplanted Mesenchymal Stem Cells: A Prerequisite for Cell Therapy

1Institute for Bio-Medical Convergence, College of Medicine, Catholic Kwandong University, Gangneung-si, Gangwon-do 210-701, Republic of Korea
2Catholic Kwandong University International St. Mary’s Hospital, Incheon Metropolitan City 404-834, Republic of Korea

Received 20 November 2014; Accepted 19 January 2015

Academic Editor: Jean-Claude Lavoie

Copyright © 2015 Seahyoung Lee et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Mason, D. A. Brindley, E. J. Culme-Seymour, and N. L. Davie, “Cell therapy industry: billion dollar global business with unlimited potential,” Regenerative Medicine, vol. 6, no. 3, pp. 265–272, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. B. E. Strauer and R. Kornowski, “Stem cell therapy in perspective,” Circulation, vol. 107, no. 7, pp. 929–934, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. K. R. Brunt, R. D. Weisel, and R.-K. Li, “Stem cells and regenerative medicine—future perspectives,” Canadian Journal of Physiology and Pharmacology, vol. 90, no. 3, pp. 327–335, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. K. Takahashi and S. Yamanaka, “Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors,” Cell, vol. 126, no. 4, pp. 663–676, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. K. Takahashi, K. Tanabe, M. Ohnuki et al., “Induction of pluripotent stem cells from adult human fibroblasts by defined factors,” Cell, vol. 131, no. 5, pp. 861–872, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. S. M. Wu and K. Hochedlinger, “Harnessing the potential of induced pluripotent stem cells for regenerative medicine,” Nature Cell Biology, vol. 13, no. 5, pp. 497–505, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. C. A. Herberts, M. S. G. Kwa, and H. P. H. Hermsen, “Risk factors in the development of stem cell therapy,” Journal of Translational Medicine, vol. 9, article 29, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. E. C. Perin, Y.-J. Geng, and J. T. Willerson, “Adult stem cell therapy in perspective,” Circulation, vol. 107, no. 7, pp. 935–938, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Pessina and L. Gribaldo, “The key role of adult stem cells: therapeutic perspectives,” Current Medical Research and Opinion, vol. 22, no. 11, pp. 2287–2300, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. F. P. Barry and J. M. Murphy, “Mesenchymal stem cells: clinical applications and biological characterization,” International Journal of Biochemistry and Cell Biology, vol. 36, no. 4, pp. 568–584, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. G. Makhoul, R. C. J. Chiu, and R. Cecere, “Placental mesenchymal stem cells: a unique source for cellular cardiomyoplasty,” Annals of Thoracic Surgery, vol. 95, no. 5, pp. 1827–1833, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. A. M. DiMarino, A. I. Caplan, and T. L. Bonfield, “Mesenchymal stem cells in tissue repair,” Frontiers in Immunology, vol. 4, article 201, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. F. Djouad, C. Bouffi, S. Ghannam, D. Noël, and C. Jorgensen, “Mesenchymal stem cells: innovative therapeutic tools for rheumatic diseases,” Nature Reviews Rheumatology, vol. 5, no. 7, pp. 392–399, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. S. M. Devine, A. M. Bartholomew, N. Mahmud et al., “Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion,” Experimental Hematology, vol. 29, no. 2, pp. 244–255, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. N. Mahmud, W. Pang, C. Cobbs et al., “Studies of the route of administration and role of conditioning with radiation on unrelated allogeneic mismatched mesenchymal stem cell engraftment in a nonhuman primate model,” Experimental Hematology, vol. 32, no. 5, pp. 494–501, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. P. Semedo, M. Burgos-Silva, C. Donizetti-Oliveira, and N. O. S. Camara, “How do mesenchymal stem cells repair?” in Stem Cells in Clinic and Research, A. Gholamrezanezhad, Ed., pp. 83–104, InTech, 2011. View at Google Scholar
  17. C. Conrad, S. Lechner, H. Niess, and R. Huss, “Basic biology and animal models in stem cell-mediated tissue regeneration,” in Topics in Tissue Engineering, N. Ashammakhi, R. Reis, and E. Chiellini, Eds., vol. 3, 2007. View at Google Scholar
  18. A. Trounson, R. G. Thakar, G. Lomax, and D. Gibbons, “Clinical trials for stem cell therapies,” BMC Medicine, vol. 9, article 52, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Wang, X. Qu, and R. C. Zhao, “Clinical applications of mesenchymal stem cells,” Journal of Hematology & Oncology, vol. 5, no. 1, article 19, 2012. View at Publisher · View at Google Scholar
  20. K. Le Blanc, F. Frassoni, L. Ball et al., “Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study,” The Lancet, vol. 371, no. 9624, pp. 1579–1586, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Le Blanc, C. Götherström, O. Ringdén et al., “Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta,” Transplantation, vol. 79, no. 11, pp. 1607–1614, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. O. N. Koç, J. Day, M. Nieder, S. L. Gerson, H. M. Lazarus, and W. Krivit, “Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH),” Bone Marrow Transplantation, vol. 30, no. 4, pp. 215–222, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. N. Meuleman, G. Vanhaelen, T. Tondreau et al., “Reduced intensity conditioning haematopoietic stem cell transplantation with mesenchymal stromal cells infusion for the treatment of metachromatic leukodystrophy: a case report,” Haematologica, vol. 93, no. 1, pp. e11–e13, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. J. S. Da Silva and J. M. Hare, “Cell-based therapies for myocardial repair: emerging role for bone marrow-derived mesenchymal stem cells (MSCs) in the treatment of the chronically injured heart,” Methods in Molecular Biology, vol. 1037, pp. 145–163, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. W. Chang, B.-W. Song, and K.-C. Hwang, “Mesenchymal stem cell survival in infarcted myocardium: adhesion and anti-death signals,” in Stem Cells and Cancer Stem Cells, vol. 10, pp. 35–43, Springer, Dordrecht, The Netherlands, 2013. View at Google Scholar
  26. J.-B. Michel, “Anoïkis in the cardiovascular system: known and unknown extracellular mediators,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 12, pp. 2146–2154, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. M. L. Taddei, E. Giannoni, T. Fiaschi, and P. Chiarugi, “Anoikis: an emerging hallmark in health and diseases,” The Journal of Pathology, vol. 226, no. 2, pp. 380–393, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. A. K. Santos, F. M. Tonelli, D. A. Silva, K. N. Gomes, L. O. Ladeira, and R. R. Resende, “The role of cell adhesion, cell junctions, and extracellular matrix in development and carcinogenesis,” in Trends in Stem Cell Proliferation and Cancer Research, pp. 13–49, Springer, 2013. View at Google Scholar
  29. P.-L. Mok, C.-F. Leong, and S.-K. Cheong, “Cellular mechanisms of emerging applications of mesenchymal stem cells,” Malaysian Journal of Pathology, vol. 35, no. 1, pp. 17–32, 2013. View at Google Scholar · View at Scopus
  30. R. A. Webster, S. P. Blaber, B. R. Herbert, M. R. Wilkins, and G. Vesey, “The role of mesenchymal stem cells in veterinary therapeutics—a review,” New Zealand Veterinary Journal, vol. 60, no. 5, pp. 265–272, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. I. Singec and E. Y. Snyder, “Inflammation as a matchmaker: revisiting cell fusion,” Nature Cell Biology, vol. 10, no. 5, pp. 503–505, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. K. Kemp, D. Gordon, D. C. Wraith et al., “Fusion between human mesenchymal stem cells and rodent cerebellar Purkinje cells,” Neuropathology and Applied Neurobiology, vol. 37, no. 2, pp. 166–178, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Cselenyák, E. Pankotai, E. M. Horváth, L. Kiss, and Z. Lacza, “Mesenchymal stem cells rescue cardiomyoblasts from cell death in an in vitro ischemia model via direct cell-to-cell connections,” BMC Cell Biology, vol. 11, article 29, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Alvarez-Dolado, R. Pardal, J. M. Garcia-Verdugo et al., “Fusion of bone-marrow-derived cells with Purkinje neurons, cardiomyocytes and hepatocytes,” Nature, vol. 425, no. 6961, pp. 968–973, 2003. View at Publisher · View at Google Scholar · View at Scopus
  35. S. C. Smith Jr., A. Collins, D. Chen et al., “Moving from political declaration to action on reducing the global burden of cardiovascular diseases: a statement fromthe Global Cardiovascular Disease Taskforce,” European Heart Journal, vol. 34, no. 46, pp. 3526–3528, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. E. M. Horwitz, D. J. Prockop, L. A. Fitzpatrick et al., “Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta,” Nature Medicine, vol. 5, no. 3, pp. 309–313, 1999. View at Publisher · View at Google Scholar · View at Scopus
  37. F. G. Teixeira, M. M. Carvalho, N. Sousa, and A. J. Salgado, “Mesenchymal stem cells secretome: a new paradigm for central nervous system regeneration?” Cellular and Molecular Life Sciences, vol. 70, no. 20, pp. 3871–3882, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. A. M. Hocking and N. S. Gibran, “Mesenchymal stem cells: paracrine signaling and differentiation during cutaneous wound repair,” Experimental Cell Research, vol. 316, no. 14, pp. 2213–2219, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Gnecchi, Z. P. Zhang, A. G. Ni, and V. J. Dzau, “Paracrine mechanisms in adult stem cell signaling and therapy,” Circulation Research, vol. 103, no. 11, pp. 1204–1219, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. H. O. Kim, S.-M. Choi, and H.-S. Kim, “Mesenchymal stem cell-derived secretome and microvesicles as a cell-free therapeutics for neurodegenerative disorders,” Tissue Engineering and Regenerative Medicine, vol. 10, no. 3, pp. 93–101, 2013. View at Publisher · View at Google Scholar · View at Scopus
  41. S. H. Ranganath, O. Levy, M. S. Inamdar, and J. M. Karp, “Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease,” Cell Stem Cell, vol. 10, no. 3, pp. 244–258, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. L. Ionescu, R. N. Byrne, T. van Haaften et al., “Stem cell conditioned medium improves acute lung injury in mice: in vivo evidence for stem cell paracrine action,” American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 303, no. 11, pp. L967–L977, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. I. Kim, S. K. Lee, J. I. Yoon, D. E. Kim, M. Kim, and H. Ha, “Fibrin glue improves the therapeutic effect of MSCs by sustaining survival and paracrine function,” Tissue Engineering, Part A, vol. 19, no. 21-22, pp. 2373–2381, 2013. View at Publisher · View at Google Scholar · View at Scopus
  44. R. Abdi, P. Fiorina, C. N. Adra, M. Atkinson, and M. H. Sayegh, “Immunomodulation by mesenchymal stem cells—a potential therapeutic strategy for type 1 diabetes,” Diabetes, vol. 57, no. 7, pp. 1759–1767, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. M. J. Hoogduijn, F. Popp, R. Verbeek et al., “The immunomodulatory properties of mesenchymal stem cells and their use for immunotherapy,” International Immunopharmacology, vol. 10, no. 12, pp. 1496–1500, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. A. I. Hoch, B. Y. Binder, D. C. Genetos, and J. K. Leach, “Differentiation-dependent secretion of proangiogenic factors by mesenchymal stem cells,” PLoS ONE, vol. 7, no. 4, Article ID e35579, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. A. Garg and P. N. Newsome, “Bone marrow mesenchymal stem cells and liver regeneration: believe the hypoxia,” Stem Cell Research and Therapy, vol. 4, article 108, 2013. View at Publisher · View at Google Scholar · View at Scopus
  48. A. N. He, Y. Jiang, C. Gui, Y. Sun, J. H. Li, and J.-A. Wang, “The antiapoptotic effect of mesenchymal stem cell transplantation on ischemic myocardium is enhanced by anoxic preconditioning,” Canadian Journal of Cardiology, vol. 25, no. 6, pp. 353–358, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. J. H. Li, N. Zhang, and J. A. Wangi, “Improved anti-apoptotic and anti-remodeling potency of bone marrow mesenchymal stem cells by anoxic pre-conditioning in diabetic cardiomyopathy,” Journal of Endocrinological Investigation, vol. 31, no. 2, pp. 103–110, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. T. Tsubokawa, K. Yagi, C. Nakanishi et al., “Impact of anti-apoptotic and anti-oxidative effects of bone marrow mesenchymal stem cells with transient overexpression of heme oxygenase-1 on myocardial ischemia (vol. 298, p. H1320, 2010),” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 303, no. 4, p. H496, 2012. View at Google Scholar
  51. A. Valle-Prieto and P. A. Conget, “Human mesenchymal stem cells efficiently manage oxidative stress,” Stem Cells and Development, vol. 19, no. 12, pp. 1885–1893, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. R. H. Lee, A. A. Pulin, M. J. Seo et al., “Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6,” Cell Stem Cell, vol. 5, no. 1, pp. 54–63, 2009. View at Publisher · View at Google Scholar · View at Scopus
  53. K.-S. Park, Y.-S. Kim, J.-H. Kim et al., “Trophic molecules derived from human mesenchymal stem cells enhance survival, function, and angiogenesis of isolated islets after transplantation,” Transplantation, vol. 89, no. 5, pp. 509–517, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. G. Uzun, D. Subhani, and S. Amor, “Trophic factors and stem cells for promoting recovery in stroke,” Journal of Vascular and Interventional Neurology, vol. 3, no. 1, pp. 3–12, 2010. View at Google Scholar
  55. S. Bruno, C. Grange, F. Collino et al., “Microvesicles derived from mesenchymal stem cells enhance survival in a lethal model of acute kidney injury,” PLoS ONE, vol. 7, no. 3, Article ID e33115, 2012. View at Publisher · View at Google Scholar · View at Scopus
  56. L. Biancone, S. Bruno, M. C. Deregibus, C. Tetta, and G. Camussi, “Therapeutic potential of mesenchymal stem cell-derived microvesicles,” Nephrology Dialysis Transplantation, vol. 27, no. 8, pp. 3037–3042, 2012. View at Publisher · View at Google Scholar · View at Scopus
  57. M. Z. Ratajczak, “The emerging role of microvesicles in cellular therapies for organ/tissue regeneration,” Nephrology Dialysis Transplantation, vol. 26, no. 5, pp. 1453–1456, 2011. View at Publisher · View at Google Scholar · View at Scopus
  58. L. de Girolamo, E. Lucarelli, G. Alessandri et al., “Mesenchymal stem/stromal cells: a new ‘cells as drugs’ paradigm. Efficacy and critical aspects in cell therapy,” Current Pharmaceutical Design, vol. 19, no. 13, pp. 2459–2473, 2013. View at Publisher · View at Google Scholar · View at Scopus
  59. D. Drago, C. Cossetti, N. Iraci et al., “The stem cell secretome and its role in brain repair,” Biochimie, vol. 95, no. 12, pp. 2271–2285, 2013. View at Publisher · View at Google Scholar · View at Scopus
  60. E. Mathieu, G. Lamirault, C. Toquet et al., “Intramyocardial delivery of mesenchymal stem cell-seeded hydrogel preserves cardiac function and attenuates ventricular remodeling after myocardial infarction,” PLoS ONE, vol. 7, no. 12, Article ID e51991, 2012. View at Publisher · View at Google Scholar · View at Scopus
  61. T. E. Robey, M. K. Saiget, H. Reinecke, and C. E. Murry, “Systems approaches to preventing transplanted cell death in cardiac repair,” Journal of Molecular and Cellular Cardiology, vol. 45, no. 4, pp. 567–581, 2008. View at Publisher · View at Google Scholar · View at Scopus
  62. M. F. Pittenger, A. M. Mackay, S. C. Beck et al., “Multilineage potential of adult human mesenchymal stem cells,” Science, vol. 284, no. 5411, pp. 143–147, 1999. View at Publisher · View at Google Scholar · View at Scopus
  63. M. Majzunova, I. Dovinova, M. Barancik, and J. Y. H. Chan, “Redox signaling in pathophysiology of hypertension,” Journal of Biomedical Science, vol. 20, no. 1, article 69, 2013. View at Publisher · View at Google Scholar · View at Scopus
  64. H. Song, M.-J. Cha, B.-W. Song et al., “Reactive oxygen species inhibit adhesion of mesenchymal stem cells implanted into ischemic myocardium via interference of focal adhesion complex,” Stem Cells, vol. 28, no. 3, pp. 555–563, 2010. View at Publisher · View at Google Scholar · View at Scopus
  65. W. Chang, B.-W. Song, J.-Y. Moon et al., “Anti-death strategies against oxidative stress in grafted mesenchymal stem cells,” Histology and Histopathology, vol. 28, no. 12, pp. 1529–1536, 2013. View at Google Scholar · View at Scopus
  66. N. Khansari, Y. Shakiba, and M. Mahmoudi, “Chronic inflammation and oxidative stress as a major cause of age-related diseases and cancer,” Recent Patents on Inflammation & Allergy Drug Discovery, vol. 3, no. 1, pp. 73–80, 2009. View at Publisher · View at Google Scholar · View at Scopus
  67. K. Urish, Inflammation and Stem Cell Transplantation, University of Pittsburgh, 2007.
  68. J.-Y. Hahn, H.-J. Cho, H.-J. Kang et al., “Pre-treatment of mesenchymal stem cells with a combination of growth factors enhances gap junction formation, cytoprotective effect on cardiomyocytes, and therapeutic efficacy for myocardial infarction,” Journal of the American College of Cardiology, vol. 51, no. 9, pp. 933–943, 2008. View at Publisher · View at Google Scholar · View at Scopus
  69. G. Lu, H. K. Haider, S. Jiang, and M. Ashraf, “Sca-1+ stem cell survival and engraftment in the infarcted heart: dual role for preconditioning-induced connexin-43,” Circulation, vol. 119, no. 19, pp. 2587–2596, 2009. View at Publisher · View at Google Scholar · View at Scopus
  70. Z. Pasha, Y. Wang, R. Sheikh, D. Zhang, T. Zhao, and M. Ashraf, “Preconditioning enhances cell survival and differentiation of stem cells during transplantation in infarcted myocardium,” Cardiovascular Research, vol. 77, no. 1, pp. 134–142, 2008. View at Publisher · View at Google Scholar · View at Scopus
  71. W. Chang, B.-W. Song, S. Lim et al., “Mesenchymal stem cells pretreated with delivered Hph-1-Hsp70 protein are protected from hypoxia-mediated cell death and rescue heart functions from myocardial injury,” Stem Cells, vol. 27, no. 9, pp. 2283–2292, 2009. View at Publisher · View at Google Scholar · View at Scopus
  72. H. Song, B.-W. Song, M.-J. Cha, I.-G. Choi, and K.-C. Hwang, “Modification of mesenchymal stem cells for cardiac regeneration,” Expert Opinion on Biological Therapy, vol. 10, no. 3, pp. 309–319, 2010. View at Publisher · View at Google Scholar · View at Scopus
  73. X. Hu, S. P. Yu, J. L. Fraser et al., “Transplantation of hypoxia-preconditioned mesenchymal stem cells improves infarcted heart function via enhanced survival of implanted cells and angiogenesis,” Journal of Thoracic and Cardiovascular Surgery, vol. 135, no. 4, pp. 799–808, 2008. View at Publisher · View at Google Scholar · View at Scopus
  74. J. Yu, S. Yin, W. Zhang et al., “Hypoxia preconditioned bone marrow mesenchymal stem cells promote liver regeneration in a rat massive hepatectomy model,” Stem Cell Research & Therapy, vol. 4, no. 4, article 83, 2013. View at Publisher · View at Google Scholar · View at Scopus
  75. S. M. Chacko, S. Ahmed, K. Selvendiran, M. L. Kuppusamy, M. Khan, and P. Kuppusamy, “Hypoxic preconditioning induces the expression of prosurvival and proangiogenic markers in mesenchymal stem cells,” American Journal of Physiology—Cell Physiology, vol. 299, no. 6, pp. C1562–C1570, 2010. View at Publisher · View at Google Scholar · View at Scopus
  76. C.-P. Chang, C.-C. Chio, C.-U. Cheong, C.-M. Chao, B.-C. Cheng, and M.-T. Lin, “Hypoxic preconditioning enhances the therapeutic potential of the secretome from cultured human mesenchymal stem cells in experimental traumatic brain injury,” Clinical Science, vol. 124, no. 3, pp. 165–176, 2013. View at Publisher · View at Google Scholar · View at Scopus
  77. A. Mishra, P. Tummala, A. King et al., “Buffered platelet-rich plasma enhances mesenchymal stem cell proliferation and chondrogenic differentiation,” Tissue Engineering. Part C, Methods, vol. 15, no. 3, pp. 431–435, 2009. View at Publisher · View at Google Scholar · View at Scopus
  78. S. S. Lin, R. Landesberg, H. S. Chin, J. Lin, S. B. Eisig, and H. H. Lu, “Controlled release of PRP-derived growth factors promotes osteogenic differentiation of human mesenchymal stem cells,” in Proceedings of the 28th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBS '06), pp. 4358–4361, New York, NY, USA, August-September 2006. View at Publisher · View at Google Scholar
  79. Y. Peng, S. Huang, Y. Wu et al., “Platelet rich plasma clot releasate preconditioning induced PI3K/AKT/NFκB signaling enhances survival and regenerative function of rat bone marrow mesenchymal stem cells in hostile microenvironments,” Stem Cells and Development, vol. 22, no. 24, pp. 3236–3251, 2013. View at Publisher · View at Google Scholar · View at Scopus
  80. B.-W. Song, W. Chang, B.-K. Hong et al., “Protein kinase C activation stimulates mesenchymal stem cell adhesion through activation of focal adhesion kinase,” Cell Transplantation, vol. 22, no. 5, pp. 797–809, 2013. View at Publisher · View at Google Scholar · View at Scopus
  81. X. Yu, D. M. Cohen, and C. S. Chen, “miR-125b is an adhesion-regulated microRNA that protects mesenchymal stem cells from anoikis,” Stem Cells, vol. 30, no. 5, pp. 956–964, 2012. View at Publisher · View at Google Scholar · View at Scopus
  82. L. Song, Y.-J. Yang, Q.-T. Dong et al., “Atorvastatin enhance efficacy of mesenchymal stem cells treatment for swine myocardial infarction via activation of nitric oxide synthase,” PLoS ONE, vol. 8, no. 5, Article ID e65702, 2013. View at Publisher · View at Google Scholar · View at Scopus
  83. Y. Tang, B. Cai, F. Yuan et al., “Melatonin pretreatment improves the survival and function of transplanted mesenchymal stem cells after focal cerebral ischemia,” Cell Transplantation, vol. 23, no. 10, pp. 1279–1291, 2014. View at Publisher · View at Google Scholar
  84. F. Huang, M.-L. Li, Z.-F. Fang et al., “Overexpression of MicroRNA-1 improves the efficacy of mesenchymal stem cell transplantation after myocardial infarction,” Cardiology, vol. 125, no. 1, pp. 18–30, 2013. View at Publisher · View at Google Scholar · View at Scopus
  85. B. D. Brewster, J. D. Rouch, M. Wang, and D. R. Meldrum, “Toll-like receptor 4 ablation improves stem cell survival after hypoxic injury,” Journal of Surgical Research, vol. 177, no. 2, pp. 330–333, 2012. View at Publisher · View at Google Scholar · View at Scopus
  86. Y. Wang, A. M. Abarbanell, J. L. Herrmann et al., “TLR4 inhibits mesenchymal stem cell (MSC) STAT3 activation and thereby exerts deleterious effects on MSC-mediated cardioprotection,” PLoS ONE, vol. 5, no. 12, Article ID e14206, 2010. View at Publisher · View at Google Scholar · View at Scopus
  87. A. A. Mangi, N. Noiseux, D. Kong et al., “Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts,” Nature Medicine, vol. 9, no. 9, pp. 1195–1201, 2003. View at Publisher · View at Google Scholar · View at Scopus
  88. L. M. McGinley, J. McMahon, A. Stocca et al., “Mesenchymal stem cell survival in the infarcted heart is enhanced by lentivirus vector-mediated heat shock protein 27 expression,” Human Gene Therapy, vol. 24, no. 10, pp. 840–851, 2013. View at Publisher · View at Google Scholar · View at Scopus
  89. X. Wang, T. Zhao, W. Huang et al., “Hsp20-engineered mesenchymal stem cells are resistant to oxidative stress via enhanced activation of Akt and increased secretion of growth factors,” Stem Cells, vol. 27, no. 12, pp. 3021–3031, 2009. View at Publisher · View at Google Scholar · View at Scopus
  90. W. Li, N. Ma, L.-L. Ong et al., “Bcl-2 engineered MSCs inhibited apoptosis and improved heart function,” Stem Cells, vol. 25, no. 8, pp. 2118–2127, 2007. View at Publisher · View at Google Scholar · View at Scopus
  91. N. Liu, Y. Zhang, L. Fan et al., “Effects of transplantation with bone marrow-derived mesenchymal stem cells modified by Survivin on experimental stroke in rats,” Journal of Translational Medicine, vol. 9, article 105, 2011. View at Publisher · View at Google Scholar · View at Scopus
  92. L. Fan, C. Lin, S. Zhuo et al., “Transplantation with survivin-engineered mesenchymal stem cells results in better prognosis in a rat model of myocardial infarction,” European Journal of Heart Failure, vol. 11, no. 11, pp. 1023–1030, 2009. View at Publisher · View at Google Scholar · View at Scopus
  93. J. Huang, Z. Zhang, J. Guo et al., “Genetic modification of mesenchymal stem cells overexpressing CCR1 increases cell viability, migration, engraftment, and capillary density in the injured myocardium,” Circulation Research, vol. 106, no. 11, pp. 1753–1762, 2010. View at Publisher · View at Google Scholar · View at Scopus
  94. C. Xiaowei, M. Jia, W. Xiaowei, and Z. Yina, “Overexpression of CXCL12 chemokine up-regulates connexin and integrin expression in mesenchymal stem cells through PI3K/Akt pathway,” Cell Communication and Adhesion, vol. 20, no. 3-4, pp. 67–72, 2013. View at Publisher · View at Google Scholar · View at Scopus
  95. I. B. Copland, S. Lord-Dufour, J. Cuerquis et al., “Improved autograft survival of mesenchymal stromal cells by plasminogen activator inhibitor 1 inhibition,” Stem Cells, vol. 27, no. 2, pp. 467–477, 2009. View at Publisher · View at Google Scholar · View at Scopus
  96. S. S. Akimov, D. Krylov, L. F. Fleischmana, and A. M. Belkin, “Tissue transglutaminase is an integrin-binding adhesion coreceptor for fibronectin,” The Journal of Cell Biology, vol. 148, no. 4, pp. 825–838, 2000. View at Publisher · View at Google Scholar · View at Scopus
  97. H. Song, W. Chang, S. Lim et al., “Tissue transglutaminase is essential for integrin-mediated survival of bone marrow-derived mesenchymal stem cells,” Stem Cells, vol. 25, no. 6, pp. 1431–1438, 2007. View at Publisher · View at Google Scholar · View at Scopus
  98. D. S. W. Benoit, M. C. Tripodi, J. O. Blanchette, S. J. Langer, L. A. Leinwand, and K. S. Anseth, “Integrin-linked kinase production prevents anoikis in human mesenchymal stem cells,” Journal of Biomedical Materials Research, A, vol. 81, no. 2, pp. 259–268, 2007. View at Publisher · View at Google Scholar · View at Scopus
  99. S.-W. Song, W. Chang, B.-W. Song et al., “Integrin-linked kinase is required in hypoxic mesenchymal stem cells for strengthening cell adhesion to ischemic myocardium,” Stem Cells, vol. 27, no. 6, pp. 1358–1365, 2009. View at Publisher · View at Google Scholar · View at Scopus
  100. S. Kidd, E. Spaeth, J. L. Dembinski et al., “Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging,” Stem Cells, vol. 27, no. 10, pp. 2614–2623, 2009. View at Publisher · View at Google Scholar · View at Scopus
  101. E. Spaeth, A. Klopp, J. Dembinski, M. Andreeff, and F. Marini, “Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells,” Gene Therapy, vol. 15, no. 10, pp. 730–738, 2008. View at Publisher · View at Google Scholar · View at Scopus
  102. C. D. Porada and G. Almeida-Porada, “Mesenchymal stem cells as therapeutics and vehicles for gene and drug delivery,” Advanced Drug Delivery Reviews, vol. 62, no. 12, pp. 1156–1166, 2010. View at Publisher · View at Google Scholar · View at Scopus
  103. D. Gjorgieva, N. Zaidman, and D. Bosnakovski, “Mesenchymal stem cells for anti-cancer drug delivery,” Recent Patents on Anti-Cancer Drug Discovery, vol. 8, no. 3, pp. 310–318, 2013. View at Publisher · View at Google Scholar · View at Scopus